Artera

Artera is an AI-powered precision oncology company developing multimodal artificial intelligence (MMAI) platforms that analyze digital pathology and clinical data to provide personalized cancer treatment recommendations. The company operates a CLIA-certified laboratory in Jacksonville, Florida, delivering laboratory-developed tests (LDTs) for cancer risk stratification and treatment guidance. ArteraAI Prostate Test, the company's flagship offering, received FDA De Novo Authorization as Software as a Medical Device (SaMD), making it the first and only AI test recommended in NCCN Clinical Practice Guidelines for Prostate Cancer. The test provides risk stratification for early-stage prostate cancer patients and predicts which NCCN Intermediate-risk patients will benefit from short-term androgen-deprivation therapy with radiation. The Prostate Test analyzes existing H&E histopathology slides without additional staining, delivers results within 1–2 days, demonstrates consistent performance across diverse populations, and is covered by Medicare and many commercial insurers. Artera also offers the ArteraAI Breast Cancer Test, providing 5- and 10-year distant metastasis risk assessment for early-stage breast cancer and identifies node-negative patients 50+ years old who may benefit from chemotherapy. The platform has been validated across dozens of large randomized phase III clinical trials. Artera maintains headquarters in Los Altos, California, with clinical laboratory operations in Jacksonville, Florida.